Evercore ISI raised the firm’s price target on Dianthus (DNTH) to $72 from $50 and keeps an Outperform rating on the shares after both doses “clearly met all the bull case efficacy bars” the firm laid out ahead of the company having announced top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized Myasthenia Gravis. Beyond the value in MG, data also “clearly derisks CIDP+MMN,” the analyst tells investors about other indications being studied.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Dianthus Therapeutics Reports Positive Phase 2 Trial Results
- Promising Phase 2 Results and Market Potential Drive Buy Rating for Dianthus Therapeutics’ Claseprubart
- Dianthus Therapeutics: Promising Phase II Results and Expanding Market Potential Justify Buy Rating
- Dianthus announces data from Phase 2 MaGic trial of claseprubart